|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,238.00 JPY | -0.18% |
|
+1.57% | +0.19% |
| 01-12 | Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026 | CI |
| 11-25 | US FDA approves Otsuka's drug for a type of kidney disease | RE |
| Capitalization | 1,230B 7.78B 6.65B 6.17B 5.79B 10.74B 713B 11.5B 70.86B 28.04B 337B 29.17B 28.58B | P/E ratio 2025 * |
19.9x | P/E ratio 2026 * | 20.5x |
|---|---|---|---|---|---|
| Enterprise value | 984B 6.22B 5.32B 4.94B 4.63B 8.59B 570B 9.2B 56.67B 22.43B 269B 23.33B 22.85B | EV / Sales 2025 * |
0.75x | EV / Sales 2026 * | 0.76x |
| Free-Float |
59.14% | Yield 2025 * |
2.67% | Yield 2026 * | 2.81% |
| 11-12 | Business Results 3Q FY2025（PDF:1,271KB） | PU |
| 31/10/25 | Otsuka : Financial Report 3Q FY2025 | PU |
| 31/10/25 | Otsuka : Business Results Data 3Q FY2025 | PU |
| 19/08/25 | Business Results 2Q FY2025（PDF:1,725KB） | PU |
| 01/08/25 | Otsuka : Financial Report 2Q FY2025 | PU |
| 1 day | -0.18% | ||
| 1 week | +1.57% | ||
| Current month | +0.19% | ||
| 1 month | -1.10% | ||
| 3 months | +6.37% | ||
| 6 months | +14.44% | ||
| Current year | +0.19% |
| 1 week | 3,155 |  | 3,308 |
| 1 month | 3,155 | | 3,322 |
| Current year | 3,155 | | 3,308 |
| 1 year | 2,815 | | 3,695 |
| 3 years | 2,072.5 | | 3,789 |
| 5 years | 1,845 | | 3,789 |
| 10 years | 1,031.25 | | 3,789 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yuji Otsuka
PSD | President | 71 | 31/07/2001 |
Koichi Hisano
CMP | Compliance Officer | - | - |
Minoru Sakurai
CTO | Chief Tech/Sci/R&D Officer | 68 | 28/02/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
Yuji Otsuka
BRD | Director/Board Member | 71 | 29/02/1992 |
| Director/Board Member | 73 | 28/02/1997 | |
| Director/Board Member | 75 | 28/02/2002 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -1.47% | 0.54% | 27 M€ | |
| +5.81% | 0.2% | 69 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.18% | +1.57% | -3.83% | +55.49% | 7.78B | |
| +0.47% | -3.38% | -22.66% | +19.26% | 30.19B | |
| +0.82% | -1.65% | +5.29% | +50.38% | 20.65B | |
| -1.72% | -3.28% | +41.81% | +44.24% | 9.33B | |
| +0.26% | +1.80% | +20.63% | +177.45% | 5.28B | |
| +1.96% | -2.31% | -25.16% | -5.23% | 4.88B | |
| +2.76% | +47.00% | +112.66% | +552.21% | 4.44B | |
| +1.86% | -8.92% | +180.06% | +261.72% | 3.18B | |
| Average | +0.78% | -1.40% | +38.60% | +144.44% | 10.72B | |
| Weighted average by Cap. | +0.50% | -1.54% | +9.86% | +77.73% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1,306B 8.26B 7.06B 6.55B 6.15B 11.4B 756B 12.21B 75.21B 29.76B 357B 30.96B 30.33B | 1,259B 7.96B 6.81B 6.32B 5.93B 10.99B 729B 11.77B 72.51B 28.7B 345B 29.85B 29.24B |
| Net income | 61.87B 391M 335M 311M 291M 540M 35.84B 579M 3.56B 1.41B 16.94B 1.47B 1.44B | 59.97B 379M 324M 301M 282M 524M 34.74B 561M 3.45B 1.37B 16.42B 1.42B 1.39B |
| Net Debt | -246B -1.56B -1.33B -1.24B -1.16B -2.15B -143B -2.3B -14.18B -5.61B -67.41B -5.84B -5.72B | -268B -1.7B -1.45B -1.35B -1.26B -2.34B -155B -2.51B -15.46B -6.12B -73.45B -6.36B -6.23B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 3,238.00 ¥ | -0.18% | 945,200 |
| 21/01/26 | 3,244.00 ¥ | +0.22% | 1,127,500 |
| 20/01/26 | 3,237.00 ¥ | +0.50% | 1,139,200 |
| 19/01/26 | 3,221.00 ¥ | -0.12% | 1,096,100 |
| 16/01/26 | 3,225.00 ¥ | +1.22% | 1,546,600 |
Delayed Quote Japan Exchange, January 22, 2026 at 06:30 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4768 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition